Healio

Plozasiran lowers APOC3, triglycerides, other lipids in high-risk populations

Please provide your email address to receive an email when new articles are posted on . Plozasiran demonstrated durable improvement in triglycerides, APOC3 and other lipid parameters for patients with ...
Nasdaq

Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the ...
EurekAlert!

FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet

BUFFALO, NY-March 20, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 5, entitled, ...
Morningstar

Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions

NEW ORLEANS, Nov. 9, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting ...
Morningstar

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

SHANGHAI, March 17, 2025 /PRNewswire/ -- Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug ...
Nasdaq

Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2002, a Phase 2b clinical study of ARO-APOC3 in ...